Figure 1. Incidence of malignant thymoma cases from 1973 to 2008 using data from the SEER database.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Original Article
Volume 8, Number 5, October 2017, pages 147-150
Metastatic Malignant Thymoma to the Abdomen: A SEER Database Review and Assessment of Treatment Strategies
Figures
Table
| Treatments | Size and location | DFI (months) | Survival (months) | Symptoms |
|---|---|---|---|---|
| Characteristics of the tumor, treatment modality, DFI, survival, and presence of additional symptoms are recorded. DFI: disease-free interval; survival based on time from metastasis to death; SM: symptoms of metastasis. | ||||
| Surgery and chemotherapy (1) | 13 × 12 cm Liver | 12 | 204 | 0/1 |
| Surgery, chemotherapy and radiation (8) | 0.15 - 18 cm Kidney, gastrointestinal tract (4), liver (3), bladder, ovary (2), perisplenic, retroperitonium | 59.9 | 28.3 | 4/8 |
| Surgery alone (2) | 4.57 cm Liver (2), gastrointestinal tract, spleen | 3.9 | NA | 1/2 |
| Chemotherapy alone (1) | NA Liver, kidney | NA | NA | 1/1 |
| Radiotherapy alone (2) | NA Liver (2), gastrointestinal tract (2) | 156 | 471 | 0/2 |
| Chemotherapy and radiotherapy (1) | NA Liver | 50 | 1/1 | |